Skip to main content

Advertisement

SpringerLink
Log in

Questioning the aim of CML therapy in the era of Imatinib?

  • Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038.

    Article  CAS  Google Scholar 

  2. Carella AM, Lerma E, Corsetti MT, Dejana A, Basta P, Vassallo F et al. Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 1999; 93: 1534–1539.

    CAS  PubMed  Google Scholar 

  3. Luzzatto L, Frassoni F, Melo JV . Imatinib: can one outwit chronic myeloid leukemia? Haematologica 2002; 9: 898–901.

    Google Scholar 

  4. La Rosee P, O'Dwyer ME, Drunker BJ . Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 2002; 16: 1213–1219.

    Article  CAS  Google Scholar 

  5. Merx K, Muller MC, Kriel S, Lahaye T, Paschka P, Schoch C et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon a. Leukemia 2002; 16: 1579–1583.

    Article  CAS  Google Scholar 

  6. Fischer T, Reifenrath C, Hess GR, Corsetti MT, Kriel S, Beck J et al. Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT). Leukemia 2002; 16: 1220–1228.

    Article  CAS  Google Scholar 

  7. Holtz MS, Slovak ML, Zhang F, Sawers CL, Forman SJ, Bathia R . Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukaemia though reversal of abnormally increased proliferation. Blood 2002; 99: 3792–3800.

    Article  CAS  Google Scholar 

  8. Hoover RR, Mahon FX, Melo JV, Daley GQ . Overcoming STI571 resistance with farnesyl-transferase inhibitor SCH66336. Blood 2002; 100: 1068–1071.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by ‘Un Taglio per la vita’ Milano, Italy.

Author information

Authors and Affiliations

  1. Department of Onco-Hematology, Division of Hematology and Bone Marrow Transplantation Unit, IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo (FG), Italy

    A M Carella

Authors
  1. A M Carella
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carella, A. Questioning the aim of CML therapy in the era of Imatinib?. Leukemia 17, 1199–1200 (2003). https://doi.org/10.1038/sj.leu.2402954

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402954

  • Springer Nature Limited

Search

Navigation